The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1263 articles
GLP-1 weight loss drugs like Ozempic and Wegovy are transforming restaurant menus. Major chains now provide smaller servings and protein-rich items as users eat less but prioritize quality. A recent poll shows 12% of Americans on these medications.
Pharmac is evaluating funding for Wegovy, a GLP-1 receptor agonist, to combat New Zealand's high obesity rates. Weight loss specialist Dr. Gerard McQuinlan says it could save taxpayers billions by preventing diseases like Type 2 diabetes. Experts weigh long-term costs, side effects, and criteria.
GLP-1 medications like Ozempic drive rapid weight loss but often trigger 'Ozempic face'—a gaunt, sagging facial look from fat volume loss. Do these drugs truly balance the effects? Evidence shows they don't selectively protect facial areas; targeted strategies are essential.
The Ozempic hype may fade as a BMJ study shows users regain lost weight within 1.5 years after stopping GLP-1 drugs. These medications reduce appetite but require lifelong use and lifestyle changes for lasting results. Obesity stems from systemic issues like convenience culture and ultra-processed foods, not just willpower.
A delivery driver was robbed of $16,000 worth of Ozempic, Mounjaro, and Trulicity outside a Bensalem, PA pharmacy. Three suspects from New York were quickly arrested after assaulting the driver. Rising demand for GLP-1 medications fuels thefts and scams, per KFF survey and BBB alerts.
Emilly dropped from 22st to 9st 2lb on Mounjaro by tackling her plateau with more water and protein. Experts reveal why 85% of GLP-1 users stall and share proven strategies to restart progress. Avoid rapid regain by combining drugs with lifestyle changes.
GLP-1 weight-loss drugs like Ozempic and Wegovy are changing how people in Connecticut eat, boosting demand for protein-rich foods to combat muscle loss. Nutrition experts and restaurateurs note shifts toward balanced meals and smaller portions. A clinical epidemiologist reveals how these drugs suppress appetite and delay gastric emptying for significant weight reduction.
The FDA's Commissioner's National Priority Voucher program aims to approve drugs in as little as one month, including anti-obesity medications. Staff and experts raise alarms over skipped steps, legal risks, and safety issues, like patient deaths in trials. Traditional six-to-10-month reviews ensure rigorous safety checks for GLP-1 drugs.
Retired NFL star Tom Brady has taken on the role of Chief Wellness Officer at eMed, a digital health company specializing in GLP-1 medications such as Wegovy and Zepbound. These popular weight-loss drugs offer game-changing results when paired with clinical guidance. Brady's move highlights the growing intersection of sports fame and evidence-based weight management.
